Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee has concluded its review of PH-762 Phase 1b trial, reporting no serious adverse events or dose-limiting toxicities.

PHIO

SBIO

<p>Phio Pharmaceuticals shares are trading higher after the company announced that the Safety Monitoring Committee has concluded its review of PH-762 Phase 1b trial, reporting no serious adverse events or dose-limiting toxicities.</p>

benzinga_article

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Phio Pharmaceuticals

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

News